08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

ARRY-614: Phase I data

The open-label, dose-escalation, U.S. Phase I ARRY-614-112 trial in 71 evaluable patients with low- to intermediate-1-risk MDS showed that oral ARRY-614 led to hematologic improvement according to 2006 International Working Group (IWG) criteria in 14...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Array BioPharma hematology, cancer news

Array said it cut headcount by 20% to about 200 to focus development and commercialization resources on hematology and cancer programs. Array said the headcount reductions came mainly from its drug discovery organization, which the...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Clinical News

ARRY-614: Phase I data

An open-label, dose-escalation Phase I trial in 44 evaluable patients with low to intermediate-1 risk MDS showed that total daily doses of 400, 600, 900 and 1,200 mg ARRY-614 led to hematologic improvement response rates...
07:00 , Aug 22, 2011 |  BioCentury  |  Strategy

Checkpoint match

With a pair of checkpoint kinase 1 inhibitors at similar stages of development, Genentech Inc. and Array BioPharma Inc. saw an opportunity for both companies to benefit by combining programs while ensuring neither has an...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Stand and deliver

Several market cap bands tracked by BioCentury did well last quarter, as investors rewarded late-stage data and transformative deals. The NYSE Arca Biotechnology Index and the BioCentury 100 each gained 7% in 2Q, while the NASDAQ...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Array BioPharma cancer news

The restructuring is expected to save about $20 million in its fiscal year ending June 30, 2012. At March 31, Array had $75.8 million in cash and a nine-month operating loss of $24.6 million. Array...
00:28 , Jun 15, 2011 |  BC Extra  |  Top Story

Array restructuring

Array BioPharma Inc. (NASDAQ:ARRY) will restructure and reduce headcount by 70 (22%) to 255 to save cash. The cuts will primarily affect discovery research and support positions. Array said it is now seeking to partner...
07:00 , Apr 26, 2010 |  BioCentury  |  Strategy

Ready to graduate

Array BioPharma Inc. believes its latest deal could be the last time it out-licenses worldwide rights to assets created by its small molecule discovery and design platform. Last week's deal with Novartis AG, plus a...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

ARRY-614: Phase I started

Array began an open-label, U.S. Phase I trial to evaluate oral ARRY-614 in about 50 patients. Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo.   Product: ARRY-614   Business: Cancer   Molecular target: p38 mitogen-activated protein kinase (p38...